Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Xentuzumab in HR+/HER2- Metastatic Breast Cancer (XENERA-1)
NCT03659136Phase 2Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Nov 2018
- Primary completion
- Aug 2021
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 11
01
Overview
A Phase 2 trial of xentuzumab in breast cancer, sponsored by Boehringer Ingelheim. Started Nov 2018; status: completed.
02
Drugs
xentuzumab
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT03659136.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03659136.